Intrexon | XON - Current Assets


Intrexon reported $23.72M in Current Assets for its fiscal quarter ending in June of 2024.





Current Assets Change Date
Agenus USD 133.44M 514K Dec/2025
Alaunos Therapeutics USD 1.99M 697K Dec/2025
Amgen USD 31.48B 2.42B Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 29.61B 890M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Incyte USD 5.48B 460.36M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
MacroGenics USD 219.94M 12.15M Dec/2025
MannKind USD 291.58M 67.26M Dec/2025
Merck USD 35.02B 8.5B Mar/2026
Novartis USD 26.61B 3.85B Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Thermo Fisher Scientific USD 22.32B 6.39B Mar/2026
Veracyte USD 488.38M 39.15M Dec/2025
Xencor USD 599.82M 81.38M Dec/2025